Gilead Sciences (GILD) Stock Analysis & AI Equity Report
Gilead Sciences (GILD) overview
Gilead Sciences (GILD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 29,443m and operating profit of USD 10,022m; the year-end share price was 122.74 USD and market capitalisation was USD 152,320m. Gilead Sciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Gilead Sciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and delivers medicines for serious diseases, with a focus on virology, oncology and other therapeutic areas. Its portfolio includes treatments and prevention medicines for HIV, therapies for viral hepatitis and COVID-19, and cancer medicines. Products are provided to patients through healthcare markets in more than 35 countries.
Generate the Gilead Sciences report
Gilead Sciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Gilead Sciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Gilead Sciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.